AstraZeneca and Bristol Myers Squibb in reported merger talks — analysts call it "odd"

Shares in AstraZeneca fell while Bristol-Myers Squibb's stock rose after reports of merger talks between the two pharmaceutical giants. A combination would create a dominant player in the cancer-drug market. However, analysts are calling the potential deal "odd" and questioning what strategic rationale would drive the two companies to merge.